Boston Scientific Slashes 2026 Profit Outlook as Watchman Woes Deepen
BSX is trading near its 52-week low of $42.2 (7.5% above the low).
Summary
Boston Scientific cut its 2026 adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41, below the $3.36 consensus, citing slower Watchman device uptake and intensifying U.S. electrophysiology competition. CEO Michael Mahoney warned these headwinds will persist into 2027, marking a significant reset from the May slowdown warning. The company also announced a global restructuring with $700M-$800M in charges aimed at $500M in savings. Q2 adjusted EPS of $0.86 beat estimates by $0.03, but the lowered outlook overshadowed the beat. Shares fell nearly 3% in morning trading. The forecast cut follows the May disclosure of Watchman softness and Monday's restructuring approval, signaling deeper operational challenges.
At the time of this announcement, BSX was trading at $45.36 on NYSE in the Life Sciences sector, with a market capitalization of approximately $67.4B. The 52-week trading range was $42.20 to $109.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.